中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Volume 42 Issue 5
May  2026
Turn off MathJax
Article Contents
Article Navigation >  Journal of Clinical Hepatology  > 2026  >  42(5): 1048-1055

Changing trend of non-alcoholic fatty liver disease among young people aged 20—44 years in East Asian countries in 1990—2023

DOI: 10.12449/JCH260509

  • Department of Hepatology，Hebei Provincial Hospital of Traditional Chinese Medicine，Shijiazhuang 050011，China

Research funding:

Key Research and Development Program of Hebei Province (223777124D);

Scientific Research Program of Hebei Provincial Administration of Traditional Chinese Medicine (2025258)

More Information
  • Corresponding author: ZHANG Jinli， zhangjinli916@163.com （ORCID： 0000-0002-7088-461X）
  • Received Date: 2025-11-24
  • Accepted Date: 2025-12-26
  • Published Date: 2026-05-25
    Abstract
  •   Objective  To investigate the disease burden of non-alcoholic fatty liver disease （NAFLD） among young people in East Asian countries （including China， North Korea， Japan， Mongolia， and South Korea） in 1990—2023， and to provide a basis for formulating and adjusting the prevention and treatment strategies for NAFLD.  Methods  Related disease burden data of NAFLD among the young people in these five East Asian countries were collected from the Global Burden of Disease 2023 （GBD 2023） database， including incidence rate， prevalence rate， and disability-adjusted life years （DALY）， and the young people were divided into groups based on country， sex， and age. Estimated annual percentage change （EAPC） was used to comprehensively evaluate the changing trend of the disease burden of NAFLD among young people from 1990 to 2023， and the Autoregressive Integrated Moving Average model was used to predict the disease burden of NAFLD among the young people in China.  Results  In 2023， the standardized incidence rates of NAFLD among the young people in China， North Korea， Japan， Mongolia， and South Korea were 926.57/100 000， 805.83/100 000， 412.66/100 000， 747.66/100 000， and 534.08/100 000， respectively； the standardized prevalence rates of NAFLD among the young people in China， North Korea， Japan， Mongolia， and South Korea were 16 817.94/100 000， 14 500.98/100 000， 8 534.40/100 000， 13 705.28/100 000， and 11 587.93/100 000， respectively； the standardized DALY rates of NAFLD among the young people in China， North Korea， Japan， Mongolia， and South Korea were 6.34/100 000， 10.18/100 000， 5.23/100 000， 47.93/100 000， and 6.76/100 000， respectively. From 1990 to 2023， there was a tendency of increase in the standardized incidence rate of NAFLD among the young people in China， North Korea， Japan， Mongolia， and South Korea， with an EAPC of 0.87%， 0.52%， 0.26%， 0.48%， and 0.87%， respectively； there was also a tendency of increase in the standardized prevalence rate of NAFLD among the young people in China， North Korea， Japan， Mongolia， and South Korea， with an EAPC of 0.99%， 0.49%， 0.24%， 0.59%， and 0.93%， respectively； conversely， there was a tendency of reduction in the standardized DALY rate of NAFLD among the young people in China， Japan， Mongolia， and South Korea， with an EAPC of -2.21%， -2.01%， -0.37%， and -4.62%， respectively， while the standardized DALY rate of NAFLD among the young people in North Korea remained relatively stable， with an EAPC of -0.01%. The subgroup analysis based on sex showed that there was a significant difference in the disease burden of NAFLD between the young people with different sexes in the five East Asian countries， and the subgroup analysis based on age showed that the incidence rate of NAFLD in young people decreased with the increase in age， while the prevalence rate and DALY rate of NAFLD increased with age. In addition， the standardized incidence rate and standardized prevalence rate of NAFLD among Chinese young people would further increase in the future， while there would be a reduction in standardized DALY rate in the future.  Conclusion  There is a significant difference in the disease burden of NAFLD in young people across different countries， sexes， and age groups. In the future， targeted prevention and treatment measures should be developed based on the distribution characteristics of the disease burden of NAFLD， in order to effectively reduce the disease burden of NAFLD among young people.

     

    • FullText(HTML)
  • loading
    • References(22)
  • [1]
    TANG J, ZHENG N, YAN YX, et al. 1990-2021 global, regional, and national analysis of the burden and trends of non-alcoholic fatty liver disease[J]. Front Med, 2025, 12: 1609816. DOI: 10.3389/fmed.2025.1609816.
    [2]
    ZHAO XY, XU D, JI W, et al. Global and Chinese burden of non-alcoholic fatty liver disease in chronic liver disease: Findings from the Global Burden of Disease Study 2021[J]. Chin Med J, 2025, 138( 14): 1741- 1751. DOI: 10.1097/CM9.0000000000003726.
    [3]
    HAO XY, SONG H, SU X, et al. Prophylactic effects of nutrition, dietary strategies, exercise, lifestyle and environment on nonalcoholic fatty liver disease[J]. Ann Med, 2025, 57( 1): 2464223. DOI: 10.1080/07853890.2025.2464223.
    [4]
    ALALWANI J, ELJAZZAR S, BASIL M, et al. The impact of health status, diet and lifestyle on non-alcoholic fatty liver disease: Narrative review[J]. Clin Obes, 2022, 12( 4): e12525. DOI: 10.1111/cob.12525.
    [5]
    LIU CL, ZHU SJ, ZHANG J, et al. Global, regional, and national burden of liver cancer due to non-alcoholic steatohepatitis, 1990-2019: A decomposition and age-period-cohort analysis[J]. J Gastroenterol, 2023, 58( 12): 1222- 1236. DOI: 10.1007/s00535-023-02040-4.
    [6]
    GU Y, GUO CN, LIU ZQ, et al. The trend in incidence of non-alcoholic fatty liver disease and its impact on cirrhosis and liver cancer: An analysis from Global Burden of Disease 2021[J]. Public Health, 2025, 242: 79- 86. DOI: 10.1016/j.puhe.2025.02.028.
    [7]
    YEUNG SL AU, BORGES MC, WONG THT, et al. Evaluating the role of non-alcoholic fatty liver disease in cardiovascular diseases and type 2 diabetes: A Mendelian randomization study in Europeans and East Asians[J]. Int J Epidemiol, 2023, 52( 3): 921- 931. DOI: 10.1093/ije/dyac212.
    [8]
    GAO YQ, YAO JJ, LIU SY, et al. Association between metabolic-associated fatty liver disease and risk of cardiometabolic multimorbidity: A disease trajectory analysis in UK Biobank[J]. Front Endocrinol, 2025, 16: 1585725. DOI: 10.3389/fendo.2025.1585725.
    [9]
    SI HAY, ONG KL, SANTOMAURO DF, et al. Burden of 375 diseases and injuries, risk-attributable burden of 88 risk factors, and healthy life expectancy in 204 countries and territories, including 660 subnational locations, 1990-2023: A systematic analysis for the Global Burden of Disease Study 2023[J]. Lancet, 2025, 406( 10513): 1873- 1922. DOI: 10.1016/S0140-6736(25)01637-X.
    [10]
    WU JX, DENG YP, TONG KL, et al. Incidence and prevalence of dysthymia among young adults in China, 1990-2021, with forecasts to 2046: An age-period-cohort analysis of the Global Burden of Disease Study 2021[J]. BMC Psychiatry, 2025, 25( 1): 238. DOI: 10.1186/s12888-025-06680-z.
    [11]
    LOU JQ, XIANG ZY, ZHU XY, et al. Trends and levels of the global, regional, and national burden of injuries from 1990 to 2021: Findings from the global burden of disease study 2021[J]. Ann Med, 2025, 57( 1): 2537917. DOI: 10.1080/07853890.2025.2537917.
    [12]
    XU K, QIAN WL, XU WJ, et al. Global, regional, and national epidemiology of childhood epilepsy from 1990 to 2021: A systematic study based on the GBD 2021[J]. Seizure, 2025, 131: 351- 360. DOI: 10.1016/j.seizure.2025.08.001.
    [13]
    HU QG, HAN KX, SHEN JP, et al. Association of weight-adjusted-waist index with non-alcoholic fatty liver disease and liver fibrosis: A cross-sectional study based on NHANES[J]. Eur J Med Res, 2023, 28( 1): 263. DOI: 10.1186/s40001-023-01205-4.
    [14]
    ZENG JJ, GU CH, WEN CL, et al. The burden of NAFLD(now referred to as MASLD)-related chronic liver disease and cirrhosis from 1990 to 2021 with projections to 2036: A comparative study of global China the United States and India[J]. Lipids Health Dis, 2025, 24( 1): 298. DOI: 10.1186/s12944-025-02750-z.
    [15]
    CHEN YF, WANG GY, HOU ZY, et al. Comparative diabetes mellitus burden trends across global, Chinese, US, and Indian populations using GBD 2021 database[J]. Sci Rep, 2025, 15( 1): 11955. DOI: 10.1038/s41598-025-96175-4.
    [16]
    YANG N, LIU TJ, LONG HY, et al. Global burden of male smoking-induced stroke, 1990-2021, and 20-year projections: An analysis of the 2021 Global Burden of Disease Study[J]. BMC Public Health, 2025, 25( 1): 2694. DOI: 10.1186/s12889-025-24021-3.
    [17]
    VANCELLS LUJAN P, VIÑAS ESMEL E, SACANELLA MESEGUER E. Overview of non-alcoholic fatty liver disease(NAFLD) and the role of sugary food consumption and other dietary components in its development[J]. Nutrients, 2021, 13( 5): 1442. DOI: 10.3390/nu13051442.
    [18]
    TROVATO FM, MARTINES GF, BRISCHETTO D, et al. Fatty liver disease and lifestyle in youngsters: Diet, food intake frequency, exercise, sleep shortage and fashion[J]. Liver Int, 2016, 36( 3): 427- 433. DOI: 10.1111/liv.12957.
    [19]
    ZHU ZX, ZHU WM, ZHOU HY, et al. Association between exposure to air pollutants and NAFLD/MAFLD: A meta-analysis[J]. BMC Public Health, 2025, 25( 1): 2672. DOI: 10.1186/s12889-025-24058-4.
    [20]
    LI YP, JI H, TIAN F, et al. Association between cumulative uric acid exposure and metabolic dysfunction-associated fatty liver disease[J]. BMC Gastroenterol, 2025, 25( 1): 497. DOI: 10.1186/s12876-025-04038-z.
    [21]
    SALMANIZADEH F, SABZEVARI S, SHAFIEIPOUR S, et al. Challenges and needs in the management of non-alcoholic fatty liver disease from the perspective of gastroenterology and hepatology specialists: A qualitative study[J]. BMC Gastroenterol, 2025, 25( 1): 396. DOI: 10.1186/s12876-025-03921-z.
    [22]
    WU XG, ZHANG T, PARK S. Dietary quality, perceived health, and psychological status as key risk factors for newly developed metabolic dysfunction-associated steatotic liver disease in a longitudinal study[J]. Nutrition, 2025, 130: 112604. DOI: 10.1016/j.nut.2024.112604.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(5)  / Tables(3)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (32) PDF downloads(8) Cited by()
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[]YesterdayPV[]TodayIP[]TodayPV[]Online[]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return